AAV2-GDNF gene therapy for Parkinson's disease

Human Gene Therapy

Volumn 20, Issue 5, 2009, Pages 430-431

  Ram, Sharona Even ^a   Galun, Eithan ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR ANTIBODY; LENTIVIRUS VECTOR; NORADRENALIN; PARVOVIRUS VECTOR; PROTEIN ANTIBODY; SEROTONIN; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 2; CLINICAL TRIAL; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DRUG TOLERABILITY; DYSKINESIA; EDITORIAL; HUMAN; IMMUNE RESPONSE; MICROINJECTION; NEURAL STEM CELL; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PUTAMEN; RHESUS MONKEY; SEROTONIN BRAIN LEVEL; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANIMALS; BRAIN; DEPENDOVIRUS; DOPAMINE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; PARKINSON DISEASE;

EID: 66149140090     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2009.1599     Document Type: Editorial

References (10)

1. Bensadoun, J.C., Déglon, N., Tseng, J.L., Ridet, J.L., Zurn, A.D., and Aebischer, P. (2000). Lentiviral vectors as a gene delivery system in the mouse midbrain: Cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp. Neurol. 164, 15-24.
2. Bobo, R.H., Laske, D.W., Akbasak, A., Morrison, P.F., Dedrick, R.L., and Oldfield, E.H. (1994). Convection-enhanced delivery of macromolecules in the brain. Proc. Natl. Acad. Sci. U.S.A. 91, 2076-2080.
3. Deierborg, T., Soulet, D., Roybon, L., Hall, V., and Brundin, P. (2008). Emerging restorative treatments for Parkinson's disease. Prog. Neurobiol. 85, 407-432.
4. Eberling, J.L., Kells, A.P., Pivirotto, P., Beyer, J., Bringas, J., Federoff, H.J., Forsayeth, J., and Bankiewicz, K.S. (2009). Functional effects of AAV2-GDNF on the dopaminergic ni-grostriatal pathway in parkinsonian rhesus monkeys. Hum. Gene Ther. 20, 511-518.
5. Johnston, L.C., Eberling, J., Pivirotto, P., Hadaczek, P., Federoff, H.J., Forsayeth, J., and Bankiewicz, K.S. (2009). Clinically relevant effects of AAV2-GDNF on the dopaminergic nigro-striatal pathway in aged rhesus monkeys. Hum. Gene Ther. 20, 497-510.
6. Kirik, D., Rosenblad, C., Bjorklund, A., and Mandel, R.J. (2000). Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: Intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigro-striatal system. J. Neurosci. 20, 4686-4700.
7. Kordower, J.H., Emborg, M.E., Bloch, J., Ma, S.Y., Chu, Y., Le-venthal, L., McBride, J., Chen, E.Y., Palfi, S., Roitberg, B.Z., Brown, W.D., Holden, J.E., Pyzalski, R., Taylor, M.D., Carvey, P., Ling, Z., Trono, D., Hantraye, P., Déglon, N., and Ae-bischer, P. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773.
8. McPhee, S.W., Janson, C.G., Li, C., Samulski, R.J., Camp, A.S., Francis, J., Shera, D., Lioutermann, L., Feely, M., Freese, A., and Leone, P. (2006). Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med. 8, 577-588.
9. Nutt, J.G., Burchiel, K.J., Comella, C.L., Jankovic, J., Lang, A.E., Laws, E.R., Jr., Lozano, A.M., Penn, R.D., Simpson, R.K., Jr., Stacy, M., and Wooten, G.F.; ICV GDNF Study Group. (2003). Randomized, double-blind trial of glial cell line-derived neu-rotrophic factor (GDNF) in PD. Neurology 60, 69-73.
10. Sauer, H., Rosenblad, C., and Bjorklund, A. (1995). Glial cell line-derived neurotrophic factor but not transforming growth factor-b3 prevents delayed degeneration of nigral dopami-nergic neurons following striatal 6-hydroxydopamine lesion. Proc. Natl. Acad. Sci. U.S.A. 92, 8935-8939.